Venrock Healthcare Capital Par Buys 14,562 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par acquired 14,562 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was purchased at an average price of $9.22 per share, for a total transaction of $134,261.64. Following the acquisition, the insider now directly owns 5,012,796 shares of the company’s stock, valued at $46,217,979.12. The trade was a 0.29 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Trading Up 5.7 %

Shares of KALV stock opened at $9.75 on Wednesday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $16.88. The firm’s fifty day simple moving average is $8.81 and its 200 day simple moving average is $10.77. The firm has a market capitalization of $481.85 million, a P/E ratio of -2.68 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. Equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on KALV shares. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target on the stock. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $23.80.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC increased its position in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the period. HighVista Strategies LLC increased its holdings in KalVista Pharmaceuticals by 4.5% in the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after buying an additional 1,432 shares during the period. JPMorgan Chase & Co. increased its holdings in KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after buying an additional 1,670 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after buying an additional 2,043 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in KalVista Pharmaceuticals by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 3,314 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).